Global Stem Cell Therapy for Diabetes and Related Conditions Market is segmented By Type (Combination Therapy, Monotherapy), By Application (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetic Foot Ulcer, Diabetic Nephropathy, Diabetic Neuropathy), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Stem Cell Therapy for Diabetes and Related Conditions Market Overview
The global stem cell therapy for diabetes and related conditions market is estimated to reach at high CAGR during the forecast period (2022-2029).
Stem Cell Therapy for Diabetes and Related Conditions Market Dynamics
The stem cell therapy for diabetes and related conditions market growth is driven by the increasing prevalence of diabetes and the growing inclination of the major diabetic populations toward use of advanced therapies to manage their diabetes has led to a surge in demand for stem cell therapy for diabetes.
Increasing prevalence of diabetes, is expected to drive the growth in the forecast period
The rising prevalence of diabetes is expected to fuel the growth of the disposable insulin pump market over the forecast period. For example, as per the International Diabetes Federation, around 463 million people in the age group of 20 to 79 years were reported to be suffering from diabetes in 2019, and it has been estimated that by 2045, the number will increase to 700 million. Furthermore, according to the same source, in 2019, diabetes caused around 4.2 million deaths. People with type 1 diabetes are increasing in most countries, and around 374 million people are expected to suffer from type 2 diabetes. Furthermore, over 1.1 children and adolescents currently have type 1 diabetes. In 2019, around 760 billion dollars were spent by the U.S. government for diabetes as healthcare expenditure.
Major side-effects of stem cell transplants are likely to hamper the market.
Stem cell transplants cause several immediate side effects such as fatigue, vomiting, low platelets and red blood cells, and diarrhea. It may also cause several long-term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. Sometimes after allogeneic transplants, Graft Versus Host Disease (GVHD) occurs if the stem cells from the donor aren’t a close enough match to the patient’s own. These risk factors may hamper the growth of the global stem cell therapy for diabetes and related conditions market size.
Stem Cell Therapy for Diabetes and Related Conditions Market Industry Analysis
COVID-19 Impact Analysis on Stem Cell Therapy for Diabetes and Related Conditions Market
The COVID-19 pandemic is expected to impact the stem cell therapy for diabetes and related conditions market negatively. Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020. COVID-19 has affected every market globally and has also impacted the global stem cell therapy for diabetes and related conditions market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
Stem Cell Therapy for Diabetes and Related Conditions Market Segment Analysis
The combination therapy segment is expected to hold largest share in this market segment
A combination of stem cell and drug therapy could reverse diabetes. The combination of stem cell transplants and antidiabetic drugs substantially improves the ability to process glucose. The metformin (Glucophage) reduces the rate at which the liver manufactures glucose, and sitagliptin (Januvia) boosts insulin production and regulates blood sugar.
The type 1 diabetes mellitus segment is expected to hold largest share in this market segment
Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction. Hence, Type 1 diabetes can be characterized most by insulin-requiring.
At present, China has the highest number of diabetes patients in the world. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026. China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.
Stem Cell Therapy for Diabetes and Related Conditions Market Geographical share
North America region holds the largest market share of global stem cell therapy for diabetes and related conditions market
The North American region is expected to hold a dominant position in the global stem cell therapy for diabetes and related conditions market over the forecast period, owing to the increasing prevalence of diabetes in the U.S. population. For instance, according to American Diabetes Association, 2018, in 2018, around 34.2 million U.S. population were reported to have diabetes. Out of which, 26.8 million were diagnosed, and 7.3 million were undiagnosed. Moreover, 14.3 million people constitute the older population (above the age of 65 years) are suffering from diabetes. Moreover, diabetes is the seventh leading cause of death in the U.S. population, with around 76,000 deaths annually in the U.S. every year.
Additionally, reimbursements policies provided by the government to the patients are expected to fuel the global stem cell therapy for diabetes and related conditions market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevalence (CDC), 2018, in the U.S., Diabetes Self-Management Education and Support (DSMES) provides education for the patients for increasing their knowledge and skills for the management of diabetes. DSMES are funded by Medicaid, which aids in reducing the health care cost of the patients.
Stem Cell Therapy for Diabetes and Related Conditions Market Competitive Landscape
The global stem cell therapy for diabetes and related conditions market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Athersys, Mesoblast, Caladrius Biosciences, Sanofi, Novo Nordisk, Cellonis Biotechnology Co. Ltd (China), Shanghai Biotechnology Co., Ltd (China). The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, NSI-566 is the stem cell therapy candidate under development by one of the key companies Neuralstem. The molecule is being developed for the treatment of individuals with diabetic neuropathy and is currently in the pre-clinical development stage. The mechanism of action of this stem cell therapy includes cell replacement that eventually leads to neurogenesis stimulation.
Stem Cell Therapy for Diabetes and Related Conditions Market Key Companies to Watch
Caladrius Biosciences
Overview: Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s platform technology leverages these cells to enable the body’s natural repair mechanisms using formulations unique to each medical indication.
Key Developments: Caladrius developing CLBS201 to treat diabetic nephropathy is under Phase 2 trials.
The global stem cell therapy for diabetes and related conditions market report would provide an access to an approx. 38 market data table, 38 figures and 200 pages.
